SGN-40

DRUG6 trials

Sponsors

Seagen Inc., Genentech, Inc.

Conditions

Lymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinMultiple MyelomaNon-Hodgkin's Lymphoma

Phase 1

Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma

CompletedNCT00525447

Seagen Inc.Multiple Myeloma

Start: 2007-08-31End: 2010-02-28Updated: 2014-10-09

A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma

CompletedNCT00556699

Genentech, Inc.Non-Hodgkin's Lymphoma

Start: 2007-12-31End: 2010-11-30Updated: 2014-03-20

Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL

CompletedNCT00655837

Seagen Inc.Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin

Start: 2008-04-30End: 2010-02-28Updated: 2014-12-18

A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

CompletedNCT00664898

Genentech, Inc.Multiple Myeloma

Start: 2008-05-31End: 2010-04-08Updated: 2022-12-12

Phase 2

Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma

CompletedNCT00435916

Seagen Inc.Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin

Start: 2006-12-31End: 2009-01-31Updated: 2015-01-07

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

TerminatedNCT00529503

Seagen Inc.Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin

Start: 2007-09-30End: 2011-05-31Updated: 2015-02-25

Related Papers

Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial

Leukemia & lymphoma/Leukemia and lymphoma2015-02-0448 citations

A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors.

2014-06-1279 citations